Teresa Almeida

Prof. Dr. Teresa Almeida

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2004 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
TATeresa Almeida
Teresa Almeida
Javier RojoJavier Rojo
Javier Rojo
Pedro M NietoPedro M Nieto
Pedro M Nieto
FPF. M. Pinto
F. M. Pinto
MHM. Hernandez
M. Hernandez
MCM. L. Candenas
M. L. Candenas
In addition to the classical neurotransmitters, acetylcholine and noradrenaline, a wide number of peptides with neurotransmitter activity have been identified in the past few years. Among them, the tachykinins substance P (SP), neurokinin A (NKA) and neurokinin B (NKB) appear to act as mediators of nonadrenergic, noncholinergic (NANC) excitatory neurotransmission. Tachykinins interact with specific membrane proteins, belonging to the family of G protein-coupling cell membrane receptors. Until now, three tachykinin receptors termed NK1 (NK1R), NK2 (NK2R) and NK3 (NK3R) have been cloned in different species. A large amount of reports suggests that these peptides are involved in nociception and neuroimmunomodulation, and in the development of different diseases such as bronchial asthma, inflammatory bowel syndrome and psychiatric disorders. Tachykinin receptor antagonists are therefore promising, therapeutically relevant agents. However, and in spite of extensive research, the obtention of selective antagonists of tachykinin receptors have revealed very difficult. An understanding of how ligands interact with their receptors is essential to permit a rational design of compounds acting selectively at the tachykinin receptor level. The major aim of the present article is to review the structure-activity data that exist for tachykinins and their receptors, with the purpose of getting insight into basic structural requirements that determine ligand/receptor interaction.

1 February 2002 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
AGAmy V. Gerstein
Amy V. Gerstein
TATeresa Almeida
Teresa Almeida
GZGuojing Zhao
Guojing Zhao
ECEric Chess
Eric Chess
ISIe‐Ming Shih
Ie‐Ming Shih
NPNickolas Papadopoulos
Nickolas Papadopoulos

1 May 2012 in Fertility and Sterility
Verified
Journal Article
Closed access
ARAntonio Cejudo Roman
Antonio Cejudo Roman
FPFrancisco Pinto
Francisco Pinto
IDIdaira Dorta
Idaira Dorta
TATeresa Almeida
Teresa Almeida
MHMariano Hernández
Mariano Hernández
LCLuz Candenas
Luz Candenas

1 June 2004 in European Journal of Pharmacology
Verified
Journal Article
Closed access
FPFrancisco Pinto
Francisco Pinto
TATeresa Almeida
Teresa Almeida
MHMariano Hernandez
Mariano Hernandez
PDPhilippe Devillier
Philippe Devillier
CACharles Advenier
Charles Advenier
LCLuz Candenas
Luz Candenas

14 October 2014 in Human Reproduction
Verified
Journal Article
Open access
PDF file
JGJ. Garcia-Ortega
J. Garcia-Ortega
FPFrancisco Pinto
Francisco Pinto
MFManuel Fernández-Sánchez
Manuel Fernández-Sánchez
NPN. Prados
N. Prados
ACA. Cejudo-Roman
A. Cejudo-Roman
LCLuz Candenas
Luz Candenas
Are neurokinin B (NKB), NK3 receptor (NK3R), kisspeptin (KISS1) and kisspeptin receptor (KISS1R) expressed in human ovarian granulosa cells? The NKB/NK3R and kisspeptin/KISS1R systems are co-expressed and functionally active in ovarian granulosa cells. The NKB/NK3R and KISS1/KISS1R systems are essential for reproduction. In addition to their well-recognized role in hypothalamic neurons, these peptide systems may contribute to the control of fertility by acting directly on the gonads, but such a direct gonadal role remains largely unknown. This study analyzed matched mural granulosa cells (MGCs) and cumulus cells (CCs) collected from preovulatory follicles of oocyte donors at the time of oocyte retrieval. The samples were provided by 56 oocyte donor women undergoing ovarian stimulation treatment. Follicular fluid samples containing MGCs and cumulus–oocyte complexes were collected after transvaginal ultrasound-guided oocyte retrieval. RT–PCR, quantitative real-time PCR, immunocytochemistry and western blot were used to investigate the pattern of expression of the NKB/NK3R and KISS/KISS1R systems in MGCs and CCs. Intracellular free Ca2+ levels, [Ca2+]i, in MGCs after exposure to NKB or KISS1, in the presence or not of tachykinin receptor antagonists, were also measured. NKB/NK3R and KISS1/KISS1R systems were expressed, at the mRNA and protein levels, in MGCs and CCs, with significantly higher expression in CCs. Kisspeptin increased the [Ca2+]i in the cytosol of human MGCs while exposure to NKB failed to induce any change in [Ca2+]i. However, the [Ca2+]i response to kisspeptin was reduced in the presence of NKB. The inhibitory effect of NKB was only partially mimicked by the NK3R agonist, senktide and marginally suppressed by the NK3R-selective antagonist SB 222200. Yet, a cocktail of antagonists selective for the NK1, NK2 and NK3 receptors blocked the effect of NKB. The granulosa and cumulus cells were obtained from oocyte donors undergoing ovarian stimulation, which in comparison with natural cycles, may have affected gene and protein expression in granulosa cells. Our data demonstrate that, in addition to their indispensable effects at the central nervous system, the NKB/NK3R and kisspeptin/KISS1R systems are co-expressed and are functionally active in non-neuronal reproductive cells of the female gonads, the ovarian granulosa cells. This work was supported by grants from Ministerio de Economía y Competitividad (CTQ2011-25564 and BFI2011-25021) and Junta de Andalucía (P08-CVI-04185), Spain. J.G.-O., F.M.P., M.F.-S., N.P., A.C.-R., T.A.A., M.H., M.R., M.T.-S. and L.C. have nothing to declare.

27 April 2015 in Critical Care
Verified
Journal Article
Open access
PDF file
LLLeonardo Lorente
Leonardo Lorente
MMMaría M Martín
María M Martín
TATeresa Almeida
Teresa Almeida
MHMariano Hernández
Mariano Hernández
LRLuis Ramos
Luis Ramos
AJAlejandro Jiménez-Sosa
Alejandro Jiménez-Sosa
Introduction: Substance P (SP) is a member of the tachykinin family of neuropeptides, which are widely distributed throughout the central nervous system (CNS) and actively involved in inflammatory processes. SP is released early following acute injury to the CNS, promoting a neurogenic inflammatory response characterized by an increase in the permeability of the blood–brain barrier and the development of vasogenic edema. High levels of SP could lead to an exacerbated inflammatory response that could be fatal for patients with traumatic brain injury (TBI). Thus, the main goal of the present study was to determine whether serum SP levels are associated with injury severity and mortality in patients with severe TBI.Methods: This multicenter, observational, prospective study was carried out in six Spanish intensive care units and included patients with Glasgow Coma Scale (GCS) scores ≤8. Patients with an Injury Severity Score ≥10 in non-cranial aspects were excluded. Blood samples were collected on day 1 of TBI to measure serum SP levels. The endpoint was 30-day mortality.Results: We found higher serum SP levels (P=0.002) in non-surviving patients (n =27) than in surviving patients (n =73). The area under the curve for serum SP levels with regard to predicting 30-day mortality was 0.70 (95% confidence interval (CI), 0.60 to 0.79;P299 pg/ml had higher 30-day mortality than patients with lower levels (hazard ratio =3.7; 95% CI, 1.75 to 7.94;P299 pg/ml were associated with 30-day mortality when we controlled for APACHE II score and Marshall computed tomography lesion classification (odds ratio (OR) =5.97; 95% CI, 1.432 to 24.851;P=0.01) and for GCS score and age (OR =5.71; 95% CI, 1.461 to 22.280;P=0.01). We found a negative association between serum SP levels and GCS score (Spearman’s ρ = −0.22;P=0.03).Conclusions: We report, for the first time to our knowledge, that serum SP levels were associated with injury severity and mortality in patients with severe TBI. These results open the possibility that SP antagonists may be useful in the treatment of patients with severe TBI.